Page 273«..1020..272273274275..280290..»

Category Archives: Stem Cell Therapy

International Stem Cell Corporation Starts Series of Preclinical Animal Studies of Neuronal Cells Derived From Human Parthenogenetic Stem Cells

Posted: July 24, 2011 at 4:04 pm

CARLSBAD, Calif. (July 20, 2011) – International Stem Cell Corporation (OTCBB: ISCO) announced today the initiation of a series of preclinical animal studies of neuronal cells derived from ISCO’s proprietary pluripotent stem cells.


The studies will evaluate the in vivo safety and tumorigenicity of neuronal cells derived from ISCO's proprietary human parthenogenetic stem cells (hpSC), as well as their ability to develop into functioning dopaminergic neuron–like cells, a key milestone towards creating a cell-based therapy for Parkinson's Disease (PD).

ISCO uses unfertilized oocytes to create human parthenogenetic stem cells, an approach that offers a number of distinct advantages over other types of human stem cells. Like human embryonic stem cells (hESCs), hpSCs are pluripotent, and thus have the capacity to become almost any cell type in the body. 

However, unlike hESCs, hpSCs can be created in a form such that cells from a single donor can be immunologically matched to millions of individuals.


Because no human embryos are ever damaged or destroyed in creating ISCO’s cells, they also avoid the ethical issues associated with embryonic hESC cells. ISCO maintains the world’s largest collection of research-grade hpSC lines.
Dr. Andrey Semechkin, the CEO of ISCO, comments: “The ability of neuronal cells to become a specific
type of neuron is one of the most important properties that these cells must have to be used in cell-based therapy of neurological disorders. These studies will bring us one step closer to our goal of being able to treat PD.”
Parkinson’s disease is a disease of the central nervous system that affects millions of people worldwide.
PD patients present a range of possible symptoms, some of which are known to be as a result of the loss of dopaminergic neurons in the mid brain. ISCO’s approach is first to derive neuronal cells successfully from hpSC and, second, to evaluate their safety, functionality and efficacy using a series of in-house in vitro and in vivo models.
About International Stem Cell Corporation
International Stem Cell Corporation is focused on the therapeutic applications of human parthenogenetic stem cells and the development and commercialization of cell-based research and cosmetic products. ISCO's core technology, parthenogenesis, results in the creation of pluripotent human stem cells from unfertilized oocytes (eggs). hpSCs avoid ethical issues associated with the use or destruction of viable human embryos. ISCO scientists have created the first parthenogenic, homozygous stem cell line that can be a source of therapeutic cells with minimal immune rejection after transplantation into hundreds of millions of individuals of differing genders, ages and racial background. This offers the potential to create the first true stem cell bank, UniStemCell™. ISCO also produces and markets specialized cells and growth media for therapeutic research worldwide through its subsidiary Lifeline Cell Technology, and cell-based skin care products through its subsidiary Lifeline Skin Care. More information is available at http://www.internationalstemcell.com .
To subscribe to receive ongoing corporate communications, please click on the following link: http://
Forward-looking Statements
Statements pertaining to anticipated developments, the potential production and benefits of stem cell
lines, and other opportunities for the company and its subsidiaries, along with other statements about
the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements. Any statements that are not historical fact (including, but not limited to statements that contain words such as "will," "believes," "plans," "anticipates," "expects," "estimates,") should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential products and the management of collaborations, regulatory approvals, need and ability to obtain future capital, application of capital resources among competing uses, and maintenance of intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements and as such should be evaluated together with the many uncertainties that affect the company's business, particularly those mentioned in the cautionary statements found in the company's Securities and Exchange Commission filings. The company disclaims any intent or obligation to update forward-looking statements.
Contacts:
International Stem Cell Corporation
760-940-6383
Ruslan Semechkin, Ph.D.
Vice President
or:
Lippert/Heilshorn & Associates
Don Markley
310-691-7100
# # #

Posted in Stem Cells, Stem Cell Therapy | Comments Off on International Stem Cell Corporation Starts Series of Preclinical Animal Studies of Neuronal Cells Derived From Human Parthenogenetic Stem Cells

The OTC Investor Article – International Stem Cell (ISCO) Aims to Become the “Intel(tm) of the Stem Cell World” By Justin Kuepper

Posted: July 24, 2011 at 4:03 pm

International Stem Cell Corp (OTCBB: ISCO), a biotechnology company focused on therapeutic biomedical research and cosmeceutical products, operating in the same industry as companies like Geron Corporation (Nasdaq: GERN) and Advanced Cell Technology Inc. (OTCBB: ACTC), aims to become the premier supplier of human cells and cell based products to the rapidly growing regenerative medicine industry.
International Stem Cell Corp (OTCBB: ISCO) specializes in manufacturing pluripotent human “partheno-genetic” stem cells that can be converted into any of the many specific types of cells that will be needed as regenerative medicine moves from the laboratory to the hospital or physician’s office.  ISCO’s cells have the same kind of ability to become any specific cell that might be needed for therapy as do the cells used by competitors like Geron Corporation (Nasdaq: GERN) and Advanced Cell Technology Inc. (OTCBB: ACTC). Unlike the cells used by these competitors, however, ISCO’s cells are not obtained from fertilized embryos that might otherwise mature into a human child. Instead, they are derived from un-fertilized human eggs that would otherwise be destroyed and have no capacity to become a human child. Thus, ISCO’s parthenogenetic stem cells have removed a major ethical barrier to the use of the most prolific class of stem cells available to science today. With its patent on using the parthenogenesis process to make the stem cells, the company plans to establish partnerships, collaborations and licensing agreements with larger pharmaceutical companies to eventually unlock significant shareholder value.
Please read the complete article at The OTC Investor here
Posted in Stem Cells, Stem Cell Therapy | Comments Off on The OTC Investor Article – International Stem Cell (ISCO) Aims to Become the “Intel(tm) of the Stem Cell World” By Justin Kuepper

International Stem Cell Corporation Starts Series of Preclinical Animal Studies of Neuronal Cells Derived From Human Parthenogenetic Stem Cells

Posted: July 24, 2011 at 4:03 pm

CARLSBAD, Calif. (July 20, 2011) – International Stem Cell Corporation (OTCBB: ISCO) announced today the initiation of a series of preclinical animal studies of neuronal cells derived from ISCO’s proprietary pluripotent stem cells.


The studies will evaluate the in vivo safety and tumorigenicity of neuronal cells derived from ISCO's proprietary human parthenogenetic stem cells (hpSC), as well as their ability to develop into functioning dopaminergic neuron–like cells, a key milestone towards creating a cell-based therapy for Parkinson's Disease (PD).

ISCO uses unfertilized oocytes to create human parthenogenetic stem cells, an approach that offers a number of distinct advantages over other types of human stem cells. Like human embryonic stem cells (hESCs), hpSCs are pluripotent, and thus have the capacity to become almost any cell type in the body. 

However, unlike hESCs, hpSCs can be created in a form such that cells from a single donor can be immunologically matched to millions of individuals.


Because no human embryos are ever damaged or destroyed in creating ISCO’s cells, they also avoid the ethical issues associated with embryonic hESC cells. ISCO maintains the world’s largest collection of research-grade hpSC lines.
Dr. Andrey Semechkin, the CEO of ISCO, comments: “The ability of neuronal cells to become a specific
type of neuron is one of the most important properties that these cells must have to be used in cell-based therapy of neurological disorders. These studies will bring us one step closer to our goal of being able to treat PD.”
Parkinson’s disease is a disease of the central nervous system that affects millions of people worldwide.
PD patients present a range of possible symptoms, some of which are known to be as a result of the loss of dopaminergic neurons in the mid brain. ISCO’s approach is first to derive neuronal cells successfully from hpSC and, second, to evaluate their safety, functionality and efficacy using a series of in-house in vitro and in vivo models.
About International Stem Cell Corporation
International Stem Cell Corporation is focused on the therapeutic applications of human parthenogenetic stem cells and the development and commercialization of cell-based research and cosmetic products. ISCO's core technology, parthenogenesis, results in the creation of pluripotent human stem cells from unfertilized oocytes (eggs). hpSCs avoid ethical issues associated with the use or destruction of viable human embryos. ISCO scientists have created the first parthenogenic, homozygous stem cell line that can be a source of therapeutic cells with minimal immune rejection after transplantation into hundreds of millions of individuals of differing genders, ages and racial background. This offers the potential to create the first true stem cell bank, UniStemCell™. ISCO also produces and markets specialized cells and growth media for therapeutic research worldwide through its subsidiary Lifeline Cell Technology, and cell-based skin care products through its subsidiary Lifeline Skin Care. More information is available at http://www.internationalstemcell.com .
To subscribe to receive ongoing corporate communications, please click on the following link: http://
Forward-looking Statements
Statements pertaining to anticipated developments, the potential production and benefits of stem cell
lines, and other opportunities for the company and its subsidiaries, along with other statements about
the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements. Any statements that are not historical fact (including, but not limited to statements that contain words such as "will," "believes," "plans," "anticipates," "expects," "estimates,") should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential products and the management of collaborations, regulatory approvals, need and ability to obtain future capital, application of capital resources among competing uses, and maintenance of intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements and as such should be evaluated together with the many uncertainties that affect the company's business, particularly those mentioned in the cautionary statements found in the company's Securities and Exchange Commission filings. The company disclaims any intent or obligation to update forward-looking statements.
Contacts:
International Stem Cell Corporation
760-940-6383
Ruslan Semechkin, Ph.D.
Vice President
or:
Lippert/Heilshorn & Associates
Don Markley
310-691-7100
# # #

Posted in Stem Cells, Stem Cell Therapy | Comments Off on International Stem Cell Corporation Starts Series of Preclinical Animal Studies of Neuronal Cells Derived From Human Parthenogenetic Stem Cells

Post Stem Cell Therapy Testimony of Cerebral Palsy

Posted: July 21, 2011 at 11:31 am

Stem cell therapy done at neurogen brain and spine institute pvt ltd.

Visit link:
Post Stem Cell Therapy Testimony of Cerebral Palsy

Posted in Stem Cell Therapy | Comments Off on Post Stem Cell Therapy Testimony of Cerebral Palsy

Stem Cell Injections at Arizona's Preferred Pain Management Center (602) 507-6550

Posted: July 20, 2011 at 5:28 am

Preferred Pain Center is the 1st southwest pain clinic to offer Regenerative Medicine with stem cell injections for pain management.

Read more from the original source:
Stem Cell Injections at Arizona's Preferred Pain Management Center (602) 507-6550

Posted in Stem Cell Therapy | Comments Off on Stem Cell Injections at Arizona's Preferred Pain Management Center (602) 507-6550

International Stem Cell Corporation Congratulates Sweden’s Karolinska University Hospital on the Creation of the World’s First Artificial Trachea

Posted: July 17, 2011 at 4:05 pm

International Stem Cell Corporation (ISCO) applauds the recent announcement by doctors at Sweden’s Karolinska University Hospital on the creation of the world’s first artificial trachea. 
ISCO would like our followers to understand that the concept of growing cells on a scaffold to treat diseases is showing success in our own research as exemplified by the following:
1) Collaboration with Cytograft in growing artificial blood vessels for treatment of lower limb ischemia. We are extremely proud and gratified to see how our FibroLife media manufactured by ISCO’s subsidiary Lifeline Cell Technology is effective in growing cells on threads used to “weave” artificial blood by Cytograft (as announced in ISCO’s recent press releases). 
2) The same technology is being used in ISCO’s work with Dr. Paul H. Chen wherein corneal epithelial cells are plated onto contact lenses (the “scaffold”) and used as a “living bandage” for laser eye surgery. 
International Stem Cell Corporation will continue to pursue the use of its cells and cell culture products in the many developing fields of regenerative medicine.
Posted in Stem Cells, Stem Cell Therapy | Comments Off on International Stem Cell Corporation Congratulates Sweden’s Karolinska University Hospital on the Creation of the World’s First Artificial Trachea

International Stem Cell Corporation Congratulates Sweden’s Karolinska University Hospital on the Creation of the World’s First Artificial Trachea

Posted: July 17, 2011 at 4:04 pm

International Stem Cell Corporation (ISCO) applauds the recent announcement by doctors at Sweden’s Karolinska University Hospital on the creation of the world’s first artificial trachea. 
ISCO would like our followers to understand that the concept of growing cells on a scaffold to treat diseases is showing success in our own research as exemplified by the following:
1) Collaboration with Cytograft in growing artificial blood vessels for treatment of lower limb ischemia. We are extremely proud and gratified to see how our FibroLife media manufactured by ISCO’s subsidiary Lifeline Cell Technology is effective in growing cells on threads used to “weave” artificial blood by Cytograft (as announced in ISCO’s recent press releases). 
2) The same technology is being used in ISCO’s work with Dr. Paul H. Chen wherein corneal epithelial cells are plated onto contact lenses (the “scaffold”) and used as a “living bandage” for laser eye surgery. 
International Stem Cell Corporation will continue to pursue the use of its cells and cell culture products in the many developing fields of regenerative medicine.
Posted in Stem Cells, Stem Cell Therapy | Comments Off on International Stem Cell Corporation Congratulates Sweden’s Karolinska University Hospital on the Creation of the World’s First Artificial Trachea

WAVE3 News Adipose Stem Cell Therapy

Posted: July 5, 2011 at 11:40 pm

Cooper, a 7-year-old Golden Retriever, had a torn ACL in both sides of his hinds - or knees. He had fat-derived stem cell therapy performed at Finchville Animal Clinic using MediVet America's new in house stem cell procedure kit.

Read more here:
WAVE3 News Adipose Stem Cell Therapy

Posted in Stem Cell Therapy | Comments Off on WAVE3 News Adipose Stem Cell Therapy

Documentary: Stem Cell Therapy for Muscular Dystrophy – Ryan Benton's Story

Posted: July 4, 2011 at 7:50 pm

This story documents Ryan Benton's most recent trip from his home in Wichita, Kansas to the Stem Cell Institute in Panama City, Panama to receive stem cell therapy for muscular dystrophy. Follow Ryan as he lands at Tocumen International airport, receives treatment and returns home. Listen to interviews from Ryan, his family and friends after his return home.

See the original post:
Documentary: Stem Cell Therapy for Muscular Dystrophy - Ryan Benton's Story

Posted in Stem Cell Therapy | Comments Off on Documentary: Stem Cell Therapy for Muscular Dystrophy – Ryan Benton's Story

Lou Gehrig’s Disease (ALS): Stem Cell Therapy – A Patient’s Perspective

Posted: July 3, 2011 at 4:08 pm

(Part 7 of 8) Dan Desmond, spoke at the "Spotlight on Disease Team Awards: ALS," an educational event presented at the CIRM Governing Board meeting on June 23, 2010. Desmond has a Master of Arts in counseling psychology and is founding director of Family Focus Christian Counseling, Inc.

Here is the original post:
Lou Gehrig's Disease (ALS): Stem Cell Therapy - A Patient's Perspective

Posted in Stem Cell Therapy | Comments Off on Lou Gehrig’s Disease (ALS): Stem Cell Therapy – A Patient’s Perspective

Page 273«..1020..272273274275..280290..»